PALI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PALI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-15), Palisade Bio's share price is $4.64. Palisade Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.16. Hence, Palisade Bio's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Palisade Bio's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 4 years, Palisade Bio's highest Price-to-Operating-Cash-Flow Ratio was 20.75. The lowest was 0.00. And the median was 0.00.
Palisade Bio's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-4.14. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.16.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 72.60% per year.
During the past 4 years, Palisade Bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.60% per year. The lowest was 72.60% per year. And the median was 72.60% per year.
The historical data trend for Palisade Bio's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Palisade Bio Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Price-to-Operating-Cash-Flow | - | - | - | - |
Palisade Bio Quarterly Data | ||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Palisade Bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Palisade Bio's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Palisade Bio's Price-to-Operating-Cash-Flow falls into.
Palisade Bio's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 4.64 | / | -19.155 | |
= |
Palisade Bio's Share Price of today is $4.64.
Palisade Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Palisade Bio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Donald Allen Williams | director | C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036 |
John David Finley | officer: Chief Financial Officer | C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
Robert J. Trenschel | director | C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
Mitchell Lawrence Jones | officer: Chief Medical Officer | 70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907 |
Robert Curtis Mcrae | officer: Chief Operating Officer | 675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075 |
Thomas Hallam | director, officer: Chief Executive Officer | C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
Michael John Dawson | officer: Chief Medical Officer | C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
Yuma Regional Medical Center | 10 percent owner | 2400 S AVENUE A, YUMA AZ 85364 |
Stephanie Diaz | director | C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
James R Neal | director | 2910 SEVENTH STREET, BERKELEY CA 94710 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
David J Mazzo | director | 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920 |
Binxian Wei | director | P.O. BOX 2231, LIVINGSTON NJ 07039 |
Kenneth C Carter | director, officer: Executive Chairman | 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
Cristina Csimma | director | 14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142 |
From GuruFocus
By Value_Insider Value_Insider • 12-01-2022
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 08-09-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Stock market mentor Stock market mentor • 01-10-2023
By sperokesalga sperokesalga • 03-01-2023
By sperokesalga sperokesalga • 05-12-2023
By PurpleRose PurpleRose • 08-12-2022
By Value_Insider Value_Insider • 11-22-2022
By PurpleRose PurpleRose • 08-17-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.